Hua Medicine (H-share) filed its Monthly Return for April 2026, confirming a stable capital structure with no changes to issued share capital and continued compliance with Hong Kong’s minimum 25% public-float requirement.

Key Highlights for April 2026

1. Authorised Share Capital • Unchanged at 2.00 billion ordinary shares with a par value of USD 0.001 each, representing authorised share capital of USD 2.00 million.

2. Issued and Treasury Shares • Issued shares: 1.06 billion; no movement during the month. • Treasury shares: none held or cancelled, leaving total issued shares unchanged at 1.06 billion.

3. Share Option Scheme Activity • Post-IPO Share Option Scheme reported 79.04 million options outstanding at 31 March 2026. • During April, 7,500 options were cancelled; no grants or exercises occurred. • Options outstanding at 30 April 2026 stood at 79.03 million, of which 15.21 million options remain available for future share issuance. • No funds were raised from option exercises in the month.

4. Other Equity Instruments • No warrants, convertibles, depositary receipts, or other share-linked agreements were outstanding or issued.

5. Compliance Confirmation • The company affirmed that all regulatory requirements under Main Board Rule 13.32D(1) were met, with the public float comfortably above the 25% threshold.

Overall, Hua Medicine’s April filing signals a month of capital stability, marked only by a minimal option cancellation and no dilution of existing shareholders.